American Society of Hirudotherapy

Cutaneous Pseudolymphoma Due to Hirudotherapy

Research article published in Turkiye parazitolojii dergisi (2019)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Clinical TrialsTemiz S et al. · Turkiye parazitolojii dergisi, 2019

Abstract

Pseudolymphoma, also known as Jessner’s lymphocytic infiltration, is a benign but usually chronic, T-cell infiltrating disease with erythematous papules and plaques usually seen on the skin of the face, neck, and back. The use of leech therapy also known as hirudotherapy has increased in recent years. Here, we report a 52-year-old male patient who had undergone hirudotherapy in his neck and developed infiltrating plaques after four months. A skin biopsy confirmed the diagnosis of Jessner’s lymphocytic infiltration. In parallel with the increasing use of hirudotherapy in recent years, the side-effect reports will likely to increase. Indications and contraindications of hirudotherapy, which is being used officially in hospitals, should be taken into consideration.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsDiagnosis, DifferentialHumansLeechingMaleMiddle AgedNeckPseudolymphomaSkin Diseases

Summary

Pseudolymphoma, also known as Jessner’s lymphocytic infiltration, is a benign but usually chronic, T-cell infiltrating disease with erythematous papules and plaques usually seen on the skin of the face, neck, and back.

Why This Matters for Hirudotherapy

Contributes clinical evidence for the therapeutic application of leech therapy.

Citation

Cutaneous Pseudolymphoma Due to Hirudotherapy.

Temiz S et al. · Turkiye parazitolojii dergisi, 2019

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Cutaneous Pseudolymphoma Due to Hirudotherapy | ASH